Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.

ABSTRACT:

Setting

Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues.

Objective

niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI).

Design

PBPK models were developed and qualified against available clinical data by integrating drug physicochemical properties and in vitro and population pharmacokinetic data into a mechanistic description of drug distribution. Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or

SUBMITTER: Rajoli RKR 

PROVIDER: S-EPMC6166436 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature